MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, associated with SPAC ticker HLXA through its merger with Helix Acquisition Corp, is a clinical-stage biopharmaceutical company focused on inflammatory diseases, with its lead asset sonelokimab targeting IL-17A and IL-17F pathways. Helix Acquisition Corp, the sponsoring blank-check vehicle, completed its IPO in 2021 and closed its de-SPAC combination with MoonLake in early 2022, resulting in the combined entity trading on Nasdaq under the ticker MLTX. The company filed an 8-K with the SEC on June 7, 2023, reflecting its status as a post-merger public company in the healthcare and biopharmaceuticals sector. For comprehensive filing history, sponsor details, and deal analytics on MoonLake and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.